4 October 2019
Canberra: Australia’s peak body representing generic and biosimilar manufacturers, the Generic and Biosimilar Medicines Association (GBMA), is delighted to announce Fresenius Kabi Australia, a leading provider of IV-Generics, Infusion Therapies, Clinical Nutrition and Medical Devices in the hospital space, as its newest member.
GBMA CEO, Ms Marnie Peterson, said she is very pleased to welcome Fresenius Kabi Australia, who officially became members on October 1.
“We are pleased to announce Fresenius Kabi Australia as our newest member to the GBMA. With their experience and expertise in the medicines industry, Fresenius Kabi Australia will become a valued and valuable part of the GBMA”.
Mr Juan Villar, Managing Director of Fresenius Kabi in Australia, said he is pleased to announce the company has joined the GBMA and is looking forward to partnering with the peak body to ensure the long-term viability of generics and biosimilars in Australia.
“With our corporate philosophy of ‘caring for life’, Fresenius Kabi is committed to putting essential medicines in the hands of people, who help patients, and to find the best answers to the challenges healthcare professionals face”, Mr Villar said.
“Our philosophy is well aligned with GBMA’s objective of making high quality medicines accessible and affordable for all Australians”.
“The uptake of biosimilars in the upcoming years will play a key role in helping to reduce the healthcare expenditure whilst making state-of-the-art therapies available to a larger and increasing number of patients. We are excited to work with the industry association”, says Juan Villar.
The GBMA is the national association representing companies that manufacture, supply and export generic and biosimilar medicines. GBMA represents all major generic medicine suppliers in Australia, accounting for more than 90% of all generic medicines dispensed in Australia. Members of GBMA ensure all Australians are offered high quality generic and biosimilar medicines, which provide affordable health outcomes that benefit all Australians. Members of GBMA take seriously their role in the responsible provision of affordable medicines in Australia, as stipulated in the National Medicines Policy. The generic and biosimilar medicines sector is a high value-add sector delivering significant health and economic benefits to the Australian public. The availability of generic medicines in this country helps to deliver:
– Timely access to affordable medicines;
– Substantial savings to the PBS;
– Thousands of highly skilled jobs; and
– Domestic manufacturing and annual exports of around $300 million.
ABOUT FRESNIUS KABI AUSTRALIA
Fresenius Kabi Australia is a subsidiary of Fresenius Kabi, a global healthcare company that specialises in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.
The company’s products and services are used to help care for critically and chronically ill patients. In the field of biosimilars, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.